Menu
Search
|

Menu

Close
X

Spark Therapeutics Inc ONCE.OQ (NASDAQ Stock Exchange Global Select Market)

90.08 USD
-- (--)
As of Jun 22
chart
Previous Close 90.08
Open --
Volume --
3m Avg Volume 221,040
Today’s High --
Today’s Low --
52 Week High 93.97
52 Week Low 41.06
Shares Outstanding (mil) 37.39
Market Capitalization (mil) 3,367.76
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.29 Mean rating from 21 analysts

KEY STATS

Revenue (mm, USD)
FY18
16
FY17
12
FY16
20
FY15
22
EPS (USD)
FY18
-1.252
FY17
-7.744
FY16
-4.276
FY15
-2.124
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.14
Price to Sales (TTM)
vs sector
127.24
8.17
Price to Book (MRQ)
vs sector
6.99
4.30
Price to Cash Flow (TTM)
vs sector
--
22.70
Total Debt to Equity (MRQ)
vs sector
0.24
17.55
LT Debt to Equity (MRQ)
vs sector
0.17
13.12
Return on Investment (TTM)
vs sector
-52.76
13.10
Return on Equity (TTM)
vs sector
-64.37
15.09

EXECUTIVE LEADERSHIP

Steven Altschuler
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Katherine High
President, Chief Scientific Officer, Director, Since 2014
Salary: $416,558.00
Bonus: $260,000.00
Jeffrey Marrazzo
Chief Executive Officer, Co-Founder, Director, Since 2016
Salary: $526,731.00
Bonus: $435,000.00
Stephen Webster
Chief Financial Officer, Since 2014
Salary: $401,346.00
Bonus: $215,000.00
John Furey
Chief Operating Officer, Since 2016
Salary: $38,077.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3737 Market St Ste 1300
PHILADELPHIA   PA   19104-5543

Phone:

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

SPONSORED STORIES